Ifosfamide as a Cause of Fanconi Syndrome

Ifosfamide-induced Fanconi syndrome is a rare complication that occurs in patients in treatment with ifosfamide. It is usually characterized by type II proximal renal tubular dysfunction, as evidenced by glycosuria, proteinuria, electrolyte loss, and metabolic acidosis. We outline two case reports o...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, Daniel, Rodelo, Joaquin, Pelaez García, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971049/
https://www.ncbi.nlm.nih.gov/pubmed/35371860
http://dx.doi.org/10.7759/cureus.22755
_version_ 1784679562385293312
author Martinez, Daniel
Rodelo, Joaquin
Pelaez García, Sebastian
author_facet Martinez, Daniel
Rodelo, Joaquin
Pelaez García, Sebastian
author_sort Martinez, Daniel
collection PubMed
description Ifosfamide-induced Fanconi syndrome is a rare complication that occurs in patients in treatment with ifosfamide. It is usually characterized by type II proximal renal tubular dysfunction, as evidenced by glycosuria, proteinuria, electrolyte loss, and metabolic acidosis. We outline two case reports of patients who received ifosfamide as chemotherapy for Ewing’s sarcoma and extranodal B-cell lymphoma.
format Online
Article
Text
id pubmed-8971049
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-89710492022-04-01 Ifosfamide as a Cause of Fanconi Syndrome Martinez, Daniel Rodelo, Joaquin Pelaez García, Sebastian Cureus Internal Medicine Ifosfamide-induced Fanconi syndrome is a rare complication that occurs in patients in treatment with ifosfamide. It is usually characterized by type II proximal renal tubular dysfunction, as evidenced by glycosuria, proteinuria, electrolyte loss, and metabolic acidosis. We outline two case reports of patients who received ifosfamide as chemotherapy for Ewing’s sarcoma and extranodal B-cell lymphoma. Cureus 2022-03-01 /pmc/articles/PMC8971049/ /pubmed/35371860 http://dx.doi.org/10.7759/cureus.22755 Text en Copyright © 2022, Martinez et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Martinez, Daniel
Rodelo, Joaquin
Pelaez García, Sebastian
Ifosfamide as a Cause of Fanconi Syndrome
title Ifosfamide as a Cause of Fanconi Syndrome
title_full Ifosfamide as a Cause of Fanconi Syndrome
title_fullStr Ifosfamide as a Cause of Fanconi Syndrome
title_full_unstemmed Ifosfamide as a Cause of Fanconi Syndrome
title_short Ifosfamide as a Cause of Fanconi Syndrome
title_sort ifosfamide as a cause of fanconi syndrome
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971049/
https://www.ncbi.nlm.nih.gov/pubmed/35371860
http://dx.doi.org/10.7759/cureus.22755
work_keys_str_mv AT martinezdaniel ifosfamideasacauseoffanconisyndrome
AT rodelojoaquin ifosfamideasacauseoffanconisyndrome
AT pelaezgarciasebastian ifosfamideasacauseoffanconisyndrome

Ejemplares similares